Cargando…

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E(2) (PGE2) that has been p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pu, Dan, Yin, Liyuan, Huang, Lin, Qin, Changlong, Zhou, Yuwen, Wu, Qiang, Li, Yan, Zhou, Qinghua, Li, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952860/ https://www.ncbi.nlm.nih.gov/pubmed/33718229 http://dx.doi.org/10.3389/fonc.2021.637504

Ejemplares similares

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
por: Pu, Dan, et al.
Publicado: (2020)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis
por: Yin, Liyuan, et al.
Publicado: (2022)

Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy
por: Hua, Jianfeng, et al.
Publicado: (2021)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

The Role of Long Non-coding RNAs in Immunotherapy Resistance
por: Zhou, Yuwen, et al.
Publicado: (2019)

Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA
por: Xue, Yuwen, et al.
Publicado: (2023)

Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies
por: He, Jian, et al.
Publicado: (2023)

Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
por: Liu, Jiayin, et al.
Publicado: (2023)

Gas6/AXL pathway: immunological landscape and therapeutic potential
por: Zhai, Xiaoqian, et al.
Publicado: (2023)

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo
por: Li, Wei, et al.
Publicado: (2011)

Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer
por: Deng, Lin, et al.
Publicado: (2020)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
por: Li, Bolei, et al.
Publicado: (2021)

Corrigendum: Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer
por: Deng, Lin, et al.
Publicado: (2020)

CCNF is a potential pancancer biomarker and immunotherapy target
por: Wei, Lifang, et al.
Publicado: (2023)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis
por: Li, Mingli, et al.
Publicado: (2020)

Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors
por: Molinari, Aurora, et al.
Publicado: (2019)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
por: Liang, Jiali, et al.
Publicado: (2022)

Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review
por: Li, Na, et al.
Publicado: (2022)

Clinical Characteristics and Outcome Between Gallbladder Squamous Cell Carcinoma and Adenocarcinoma: A Propensity Matched Analysis Based on the Surveillance, Epidemiology, and End Results Database
por: Chen, Xiaorong, et al.
Publicado: (2022)

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
por: Kwilas, Anna R., et al.
Publicado: (2012)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors
por: Lin, Binwei, et al.
Publicado: (2021)

Combinations of Immunotherapy and Radiation in Cancer Therapy
por: Vatner, Ralph E., et al.
Publicado: (2014)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
por: Butters, Oliver, et al.
Publicado: (2019)

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance
por: Ma, Feng, et al.
Publicado: (2023)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

En bloc resection of the recurrent pleural mesothelioma and reconstruction of the chest wall after immunotherapy: A case report
por: Qin, Changlong, et al.
Publicado: (2023)

METTL3 Is Associated With the Malignancy of Esophageal Squamous Cell Carcinoma and Serves as a Potential Immunotherapy Biomarker
por: Zhou, Yubin, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
por: Zhu, Xiaoxi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i27mlqdvlrjdfbsv0l4unbcqbe